BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25038008)

  • 1. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation.
    Patel VR; Hofstetter WL; Correa AM; Agarwal A; Rashid A; Bhutani MS; Lin SH; Ajani JA; Swisher SG; Maru DM
    Ann Thorac Surg; 2014 Sep; 98(3):1064-71. PubMed ID: 25038008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy.
    Corsini EM; Foo WC; Mitchell KG; Zhou N; Maru DM; Ajani JA; Hofstetter WL; ; Correa AM; Antonoff MB; Lin SH; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL
    J Thorac Cardiovasc Surg; 2021 Nov; 162(5):1404-1412.e2. PubMed ID: 33010880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Role for Preoperative Chemoradiation in Esophageal Signet Ring Cell Adenocarcinomas?
    Gronnier C; Bekkar S; Messager M; Piessen G; Mariette C
    Ann Thorac Surg; 2015 Jun; 99(6):2253-4. PubMed ID: 26046895
    [No Abstract]   [Full Text] [Related]  

  • 5. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
    van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
    Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signet Ring Cell Histology Confers Worse Overall Survival in Treated Esophageal Adenocarcinoma.
    Tang A; Rappaport J; Raja S; Bribriesco AC; Sudarshan M; Siddiqui HU; Raymond D; Murthy SC; Ahmad U
    Ann Thorac Surg; 2021 Jan; 111(1):214-222. PubMed ID: 32579884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
    Wang KL; Yang Q; Cleary KR; Swisher SG; Correa AM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Oct; 107(7):1467-74. PubMed ID: 16955509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation.
    Charalampakis N; Nogueras González GM; Elimova E; Wadhwa R; Shiozaki H; Shimodaira Y; Blum MA; Rogers JE; Harada K; Matamoros A; Sagebiel T; Das P; Minsky BD; Lee JH; Weston B; Bhutani MS; Estrella JS; Badgwell BD; Ajani JA
    Oncology; 2016; 90(5):239-47. PubMed ID: 27046280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
    Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
    Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma.
    Solomon D; Abbas M; Feferman Y; Haddad R; Perl G; Kundel Y; Morgenstern S; Menasherov N; Kashtan H
    Ann Surg Oncol; 2021 Sep; 28(9):4929-4940. PubMed ID: 33709175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of signet ring cell histology in esophageal adenocarcinoma.
    Yendamuri S; Huang M; Malhotra U; Warren GW; Bogner PN; Nwogu CE; Groman A; Demmy TL
    Cancer; 2013 Sep; 119(17):3156-61. PubMed ID: 23719932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.
    Harada K; Patnana M; Wang X; Iwatsuki M; Murphy MAB; Zhao M; Das P; Minsky BD; Weston B; Lee JH; Bhutani MS; Estrella JS; Shanbhag N; Ikoma N; Badgwell BD; Ajani JA
    Surg Today; 2020 Oct; 50(10):1223-1231. PubMed ID: 32409870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.